Mountview Estates: NAV Creeps To New £92 Per Share High Despite Weakest H1 For 5 Years

07 December 2018
By Maynard Paton

Update on Mountview Estates (MTVW).

Event: Interim results for the six months to 30 September 2018 published 22 November 2018.

Summary: The property-trading specialist revealed its weakest first-half performance since 2013 after selling eleven fewer houses than this time last year. Furthermore, the 133% investment return achieved from those disposals was below MTVW’s ten-year average. Nonetheless, net asset value (NAV) still managed to creep to a fresh £92 per share high. Meanwhile, dissident shareholders continue to vote against MTVW’s directors and may be growing in number. The £100 shares do not appear expensive on an NAV and yield basis, and I have recently bought more.

Read more

[SharePad] Screening For My Next Long-Term Winner: Mattioli Woods

***SharePad New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

07 December 2018
By Maynard Paton

Many years ago, one of my favourite sources for investment ideas was the Financial Times.

However, the FT’s articles did not interest me, and nor did the Lex column.

Instead, I studied a small table that was tucked away on those pages that listed every share price.

You see, this table named the shares that traded at a 52-week low — and I wanted to learn more about the companies that the market disliked.

Indeed, I hoped a decent business would occasionally fall out of favour, join that table and become worthy of investigation.

These days, SharePad can do all of this 52-week-low screening — and much more besides — in an instant.

Let me now explain how I employ SharePad to scan for shares hitting fresh lows. I will then provide a case study using Mattioli Woods outlining what I then check.

Simply click here to read my Mattioli Woods article for SharePad.

Maynard Paton

[SharePad] Screening For My Next Long-Term Winner: Warpaint London

***SharePad New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

23 November 2018
By Maynard Paton

One of my favourite ways of assessing companies is by calculating their turnover per employee.

The theory is simple: companies that produce high sales from few people are often simpler to manage and grow than businesses that produce low sales from many people.

In fact, if you can find a business that can expand significantly without needing to take on huge numbers of extra staff, then perhaps you have found a business with a product that actually sells itself.

Suffice to say, companies blessed with products that sell themselves are generally good for us investors!

Let’s now use SharePad to investigate Warpaint London — a cosmetics business with high sales per employee.

Simply click here to read my Warpaint London article for SharePad.

Maynard Paton

Castings: H1 Results Reveal Machining Turnaround Delayed By 2 Years While Depreciation Review Inflates Group Profit By 10%

15 November 2018
By Maynard Paton

Update on Castings (CGS).

Event: Interim results for the six months to 30 September 2018 published 13 November 2018.

Summary: CGS’s results were acceptable but contained several irritating drawbacks. In particular, a recovery at the engineer’s troubled machining division has been seemingly postponed for two years. Furthermore, management has now downgraded customer demand from “strong” to “steady”. Oh, and a depreciation review inflated group profit by 10%. CGS does have strengths — not least its cash pile and dividend history — but I suspect the firm’s stalled earnings will keep the shares marooned for now. I continue to hold.

Read more

[Event] Join Me At The ShareSoc Masterclass: 27 November, London

10 November 2018
By Maynard Paton

I just thought I would let you know about my participation in an upcoming investor event.

The ShareSoc Masterclass will be hosted at the Clayton Hotel, Chiswick, London on Tuesday, 27 November, and will run from 5:00pm to 7:30pm.

The event is a panel session, and the panellists are:

* Leon Boros (ISA millionaire and acquisition consultant);
* Professor Glen Arnold (Investment author and  Deep Value Shares newsletter editor);
* Graham Neary (Cube.Investments founder and Stockopedia writer), and;
* Me

Glen and Graham will each spend 20 minutes presenting an insightful investing topic. The rest of the evening will be dedicated to the panel answering investment questions from the audience. I am looking forward to taking part and I am sure the occasion will be very educational and entertaining.

ShareSoc is a not-for-profit organisation that is dedicated to the support of individual investors. Event tickets are currently on sale and are apparently selling fast.

Just click here to read full details of the event and to secure your ticket.

I hope to see you there.

Maynard Paton

[SharePad] Screening For My Next Long-Term Winner: Zytronic

***SharePad New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

10 November 2018
By Maynard Paton

You might recall from the other week that I decided to unearth the market’s most reliable dividend payers.

My theory was simple — companies with illustrious payout records should provide much more reliable returns during market setbacks than a collection of more speculative shares.

I therefore employed SharePad to identify companies that had lifted their dividend every year for at least the last ten years… and by a compound average of 5% or more.

I also limited the search to companies that offered a forecast payout yield of 4%-plus.

My initial screening pinpointed PayPoint — although my SharePad trawling did reveal another interesting name: Zytronic.

You see, this particular small-cap also boasted an extended history of rising dividends…

…but in addition, offered a 5.7% forecast yield and net cash that represented a substantial 22% of its market cap.

Simply click here to read my Zytronic article for SharePad.

Maynard Paton

Oleeo: The 4:28pm Results Revealed A Further Earnings Slump As Anonymous Tip-Off Corrects My HMRC Mistake

07 November 2018
By Maynard Paton

Update on Oleeo (OLEE).

Event: Preliminary results for the twelve months to 31 July 2018 published 02 November 2018.

Summary: Publishing results at 4:28pm on a Friday is never a good sign. And sure enough, the recruitment software outfit warned of yet another profit slump. Still, at least revenue inched to a new record as the firm enjoyed greater subscription income. Meanwhile, an anonymous tip-off has set me straight about OLEE’s contract with HMRC — the deal appears not to have been lost after all. All I can do now with this illiquid share is hope for an earnings rebound. I continue to hold.

Read more

System1: H1 Results Could Mean The P/E Is Just 9… Assuming The Ad Ratings Service Eventually Becomes A Money-Spinner (I’m Not Sure)

06 November 2018
By Maynard Paton

Update on System1 (SYS1).

Event: Interim results for the six months to 30 September 2018 published 02 November 2018.

Summary: A couple of earlier updates had already signalled this lacklustre first-half performance. Indeed, several references to competitive pricing and re-designed products implied the advertising research specialist may no longer be the ‘pioneering’ force it once was. Furthermore, the new Ad Ratings service could be hard pushed to become a real money-spinner and return the group to growth. That said, margins remain good, there is cash in the bank and the P/E might be 9… if you believe some significant development expenditure will eventually pay off. I continue to hold.

Read more

Tristel: 2018 Profit Advances 14% (Before Hefty Share-Based Payments) As Bizarre Management Decision Delays FDA Application Once Again

26 October 2018
By Maynard Paton

Update on Tristel (TSTL).

Event: Final results for the twelve months to 30 June 2018 published 17 October 2018 and shareholder presentation hosted 18 October 2018.

Summary: I was broadly satisfied with these full-year figures, which set new records for revenue, profit and the dividend. However, the statement and City presentation provided numerous little niggles — not least a bizarre management decision that has delayed product approval within the United States for a further six months. Still, TSTL’s collection of medical disinfectants continue to produce attractive accounts and perhaps their biocidal qualities have been underlined by recent deals with the NHS and Parker Laboratories. I continue to hold.

Read more

[SharePad] Screening For My Next Long-Term Winner: PayPoint

***SharePad New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

26 October 2018
By Maynard Paton

I don’t know about your shares, but my portfolio was thumped during this month’s market sell-off.

The drubbing prompted me to consider whether I should remain invested in my racy growth stocks and contrarian recovery plays — or seek out some alternative opportunities instead.

My latest SharePad trawling has therefore centred on dividends — which for many of us are the gold standard of investing dependability.

I mean, employ the right directors at the right business, and shareholders can sit back, relax and enjoy consistent payout advances…

…regardless of what happens to the stock market, the economy and just about everything else!

Simply click here to read my PayPoint article for SharePad.

Maynard Paton

Bioventix: 2018 Results Suggest 20% Underlying Growth But Disappointing Troponin Sales Leave Lofty P/E Open To Debate

12 October 2018
By Maynard Paton

Update on Bioventix (BVXP).

Event: Preliminary results for the year to 30 June 2018 published 08 October 2018.

Summary: The antibody specialist delivered yet another set of record results, with my number-crunching indicating underlying growth of 20%.  However, I was disappointed to discover early sales of the important new troponin product had been below expectations — and may have left the lofty P/E valuation open to debate (at least for now). Still, the business continues to exhibit magnificent accounts while a special dividend for the third consecutive year underpins the board’s confidence. I continue to hold.

Read more

[SharePad] Screening For My Next Long-Term Winner: Character

***SharePad New Subscriber Special Offer***
Readers of my blog can claim one month of free data. Click here for details.

08 October 2018
By Maynard Paton

I have written another article for SharePad.

This time my screening has short-listed Character (CCT) as a possible longer-term investment.

The attraction here is a quite extraordinary story about buybacks.

You see, since 2006, this small-cap has bought back shares every year to reduce its overall share count by a huge 60%.

What’s more, the purchases have been an exemplary use of surplus cash. The average price paid was 143p, and the shares currently trade above 500p.

Needless to say, I now ask myself whether further significant buybacks at Character should prompt us to invest, too.

Simply click here to read my Character article for SharePad.

Maynard Paton

Getech: H1 Revenue Hits A 7-Year Low And For Now My Hopes Rest On A Stronger Oil Price

08 October 2018
By Maynard Paton

Update on Getech (GTC).

Event: Interim results for the six months to 30 June 2018 published 28 September 2018.

Summary: These figures were not as good as I had hoped. The lowest first-half sales for seven years created a not-insignificant operating loss and left cash flow dependent on tax refunds. Still, the geoscience software specialist talked of a stronger second half and I remain hopeful the accounts will eventually showcase the high margins and expanding revenue the directors continue to predict. For the time being, I just have to trust a stronger oil price can one day tempt GTC’s customers to increase their spending. I continue to hold.

Read more

Q3 2018: 1 Top-Up And My SharePad Side-Income

03 October 2018
By Maynard Paton

Happy Wednesday! I hope you continue to find my Blog useful… and that your shares served you well during the summer.

Unfortunately, my portfolio has not exactly sizzled during the last three months.

In particular, notable price advances from Andrews Sykes and Mincon were offset by further declines at System1 and Tasty. Elsewhere, highly rated holdings FW Thorpe and Tristel have come off the boil, while stagnant positions Mountview Estates and Oleeo remain, well, stagnant.

It has all meant that, nine months into the year, I am up 4.4% versus a 1.0% total return produced by the FTSE 100*. No doubt about it, my gains this year have been far from stellar. But following two years of lagging the index, I will happily take my current outperformance for 2018.

Recent RNSs from my shares have been broadly positive. Once again there was a mix of satisfactory to lacklustre statements, and I am glad no major horror stories emerged.

And I did venture to one AGM, which helped prompt my portfolio’s only Q3 trading.

Read more

Andrews Sykes: I Had Expected H1 Sales To Grow By More Than 7% Following The Heavy Snow And Extended Heatwave

01 October 2018
By Maynard Paton

Update on Andrews Sykes (ASY).

Event: Interim results for the six months to 30 June 2018 published 28 September 2018.

Summary: Widespread snow followed by a glorious heatwave were always going to prompt demand for ASY’s heating products and air conditioners during this first half. However, I did expect the equipment hire firm to have recorded sales growth in excess of the 7% actually reported. Still, operating profit gained 14% while the accounts continue to showcase high margins and surplus cash. Plus, the second-half ought to show bumper figures and help deliver the firm’s best-ever annual performance. I continue to hold.

Read more